Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

NCT05154396 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Neratinib

Sponsor

Chinese Academy of Medical Sciences